ACI-35030 is under clinical development by AC Immune and currently in Phase II for Tauopathies. According to GlobalData, Phase II drugs for Tauopathies does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ACI-35030 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ACI-35030 overview
ACI-35.030 is under development for the treatment of Alzheimer's disease and other tauopathies. It is a liposomal vaccine and is based on SupraAntigen technology platform. The vaccine candidate targets phospho-Tau (pTau). It is administered through intramuscular route.
AC Immune overview
AC Immune is a clinical-stage biopharmaceutical company that discovers, designs and develops proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The company develops drugs based on its two proprietary technology platforms: SupraAntigen and Morphomer. Its technology platforms help the company to design, discover and develop antibodies, small molecules and vaccines. AC Immune’s product pipeline includes nine therapeutic product candidates and three diagnostic product candidates. The company’s lead product candidate crenezumab, is a monoclonal antibody that targets abeta in cognitive healthy individuals who are at risk of developing familial Alzheimer’s Disease (fAD). AC Immune is headquartered in Lausanne, Switzerland.
For a complete picture of ACI-35030’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
